SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria
about
Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west UgandaThe spread, treatment, and prevention of HIV-1: evolution of a global pandemicTopical microbicides for prevention of sexually transmitted infectionsInterventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infectionBlocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responsesAdvances in HIV microbicide developmentMicrobicides: a new hope for HIV preventionMicrobicides and their potential as a catalyst for multipurpose sexual and reproductive health technologiesNew Biomedical Technologies and Strategies for Prevention of HIV and Other Sexually Transmitted InfectionsAdherence in the CAPRISA 004 tenofovir gel microbicide trialStampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDSIn vitro surfactant structure-toxicity relationships: implications for surfactant use in sexually transmitted infection prophylaxis and contraceptionRectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized micePostcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trialsStructure activity relationship of dendrimer microbicides with dual action antiviral activityDevelopment of a prospective cohort of HIV Exposed Sero-Negative (HESN) individuals in Jos Nigeria.Abasic phosphorothioate oligomers inhibit HIV-1 reverse transcription and block virus transmission across polarized ectocervical organ cultures.HIV-prevention science at a crossroads: advances in reducing sexual risk.Nanotechnology and HIV: potential applications for treatment and prevention.Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.Overview of microbicides for the prevention of human immunodeficiency virus.The importance of the vaginal delivery route for antiretrovirals in HIV prevention.Efficacy dilution in randomized placebo-controlled vaginal microbicide trialsSemi-solid gels function as physical barriers to human immunodeficiency virus transport in vitro.Surfactants as microbicides and contraceptive agents: a systematic in vitro study.The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trialEffectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria.Interim data monitoring to enroll higher-risk participants in HIV prevention trialsTargeting Trojan Horse leukocytes for HIV prevention.Whither or wither microbicides?Notes on the frequency of routinely collected and self-reported behavioral data in HIV prevention trials.Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse.Advances in the Development of Microbicides for the Prevention of HIV Infection.State of the science of adherence in pre-exposure prophylaxis and microbicide trials.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safetyContraception and pregnancy in microbicide trials.Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization.Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety.
P2860
Q21203732-D05B379D-9144-4763-91ED-1D7557A6C89EQ22241890-870E7766-CDF6-4F8C-8CC8-552A4352EE82Q24202832-66C31DFF-681E-4254-A876-DE61BAC5B168Q24234875-4A4B5F3E-F52A-4A50-9E08-AD062BCED25BQ26774878-93BE0775-CC63-45A1-AE3E-4EEDE5F51833Q26852858-2AA949E6-7244-4DAC-A20F-78E2EDE64C21Q27022779-8E7DB55A-7FE8-4547-905C-473065D92F63Q27026257-2BBFC3EE-A144-44F8-8307-EF8584324D46Q28072213-18ED0680-0142-4DA1-B74C-263666C115E2Q28236148-ABC3DEC2-DB05-40DC-850C-9E5983E36FE0Q28260539-1C1E067A-68A9-45FB-82AF-450F47CA9CEFQ28478153-006EC4D2-AAAC-4835-B030-F0616BB7E9E3Q28488527-6E02A217-7D13-454B-826A-EDE8B03AAD41Q28749211-C7B0AFEF-30AE-45F9-8FF1-CDA2A0747274Q28749596-27DC1BE4-6136-4ECD-AF0B-B46C83C6788FQ30151894-EFB1226A-BD5D-441E-8015-487D46236EB4Q30366821-0BD30602-2F60-4778-A968-21D77E1813C4Q30378142-72D7DD22-CA08-485C-9922-D64FF210AD81Q30393980-F97CC626-2F26-4096-800B-C79B1D9D6C7FQ30412592-5FE2D8A3-59F1-4E86-BAB9-005EEFAD3E9CQ30413777-A3BFCCED-697C-479C-AE99-73C7BC315763Q30414890-5BF26950-F065-4C1B-9AE4-F87C36969151Q30491264-D96B976F-E7C4-4488-B8E0-F69F38C45867Q30499386-BED80200-1523-4703-965B-2C8F4C424779Q33358081-3F3455CE-6AE6-487C-8E09-86687165CB09Q33378486-8D82CEC2-FDCF-430D-B57B-B92629117072Q33386027-47B388F7-2C3D-4E56-8F9F-E0E162A57B5AQ33473028-7580DBE4-130D-4A34-9B57-413CF6A06BABQ33518390-0539997E-4CC1-4D2E-8BB1-E158D525A163Q33715907-25990160-F438-44F5-B65C-AF057C7E81CAQ33722251-8E389A08-AE89-4A87-942B-3ACCEB0B82D0Q33750747-6524701F-AC10-4842-905B-0440E907D193Q33762924-7442F3DD-782B-4F20-A54F-BDEC0AF57A4BQ33798685-B826E742-BB38-4B64-81AD-5D4E1F4076A5Q33821090-0F69C2DD-ACFF-4957-869E-1CE7F3370518Q33880947-C6E04D29-402C-4983-97B2-D26B053545A0Q33924850-04A6FED7-30A2-41EE-BEA4-C7CCD25555FEQ33955105-E8901EDE-787E-4B41-8455-BFC5A9A1ECDDQ34030735-343EF86D-C6DC-4FAD-9771-30BDE0B996D0Q34078011-12B0C11A-426D-4F44-B52F-90BC71DFAE2F
P2860
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@ast
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@en
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@en-gb
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@nl
type
label
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@ast
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@en
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@en-gb
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@nl
prefLabel
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@ast
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@en
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@en-gb
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@nl
P2093
P2860
P921
P3181
P1433
P1476
SAVVY vaginal gel (C31G) for p ...... ed controlled trial in Nigeria
@en
P2093
Adesina Adeiga
Anja Lendvay
Fatimah Obadaki
M Onikepe Olayemi
Paul J Feldblum
Rashidi Bakare
Silver Wevill
Wes Rountree
P2860
P3181
P356
10.1371/JOURNAL.PONE.0001474
P407
P50
P577
2008-01-01T00:00:00Z